China · Delayed Price · Currency is CNY Shanghai Fosun Pharmaceutical (Group) Company Description
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. engages in the pharmaceutical business in Mainland China and internationally.
It operates through five segments: Pharmaceuticals, Medical Devices and Medical Diagnosis, Medical Services, Medical Distribution and Retail, and Others.
The company is involved in the pharmaceutical manufacturing in the therapeutic areas of solid oncology, including tumors and hematologic malignancies, as well as immune-inflammatory disorders, metabolism and digestive systems, anti-infection, central nervous system, cardiovascular system, and APIs and intermediates.
It also offers mRNA vaccines; medical aesthetic devices, such as medical aesthetic capital equipment, aesthetic dentistry, injectables, and personal care business units; mechanical ventilation devices under the Breas brand; and mobile pre-hospital care; professional in-hospital surgery and covers medical devices; and high-end surgical robots and medical consumables.
In addition, the company provides diagnostics solutions comprising biochemical diagnostics, immune diagnostics, molecular diagnostics, microbiological diagnostics, pathological diagnostics, and chronic care management; and healthcare services, specialized medical treatment, online and offline medical services, and insurance services.
Further, it engages in the operation of hospitals; and distribution and retail of healthcare products.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. was founded in 1994 and is based in Shanghai, China.
| Country | China |
| Founded | 1994 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 40,603 |
| CEO | Yi Liu |
Contact Details
Address: Building A Shanghai, 200233 China | |
| Phone | 86 21 3398 7000 |
| Website | fosunpharma.com |
Stock Details
| Ticker Symbol | 600196 |
| Exchange | Shanghai Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | CNE000000X38 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Wenjie Zhang | Co-President and Co-Chief Executive Officer of Innovative Medicines Division |
| Wang Xingli M.D., Ph.D. | Co-President, Chief Executive Officer of Innovative Medicines Div., Chairman of Global Research & Development Center |
| Jing Li | Co-President and Chief Executive Officer of Established Medicines Manufacturing and Supply Division |
| Dr. Yi Liu | President, Chief Executive Officer, Co-Chair of the Innov Drugs, Chair, CEO of the Diag and Therap Tech & Exec Director |
| Xiaohui Guan | Executive Co-Chairman |
| Yuqing Chen | Executive Chairman |
| Rongli Feng | Executive President and Chief Human Resources Officer |
| Zhanyu Chen | Senior Vice President and Chief Financial Officer |
| Yue Zhu | Vice President and GM of Legal Department |
| Kexin Wang | Executive Director |